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A B S T R A C T
Forensic mRNA profiling assays normally include a set of vaginal-specific markers. Although it is known that
vagina undergoes characteristic age-related morphological and physiological changes over a lifetime, few studies
have evaluated the efficacy of proposed forensic vaginal mRNA markers in women from different age groups.
In this collaborative study involving ten GeFI (Italian working group of ISFG) laboratories, a 19-plex mRNA
profiling assay including three vaginal-specific markers (CYP2B7P1, MUC4, MYOZ1) was tested in a collection of
vaginal swabs obtained from female volunteer donors in their reproductive years (n= 84) and postmenopausa
(n=55).
Differential expression of vaginal markers in the two age categories was assessed by means of: a) overall
success rate of mRNA profiling (vaginal mucosa “observed” in the tested sample according to scoring protocol)
b) average peak height ratios between vaginal-specific markers within mRNA profiling replicates.
Other factors potentially influencing mRNA profiling outcomes, like time interval between vaginal swab
collection and analysis, concurrence of menstrual cycle and recent sexual activity at the time of sampling were
also investigated.
1. Introduction
In the past few years mRNA profiling has emerged as a powerful tool
for the identification of body fluids of forensic interest, including va-
ginal mucosa. Vaginal mucosa is a highly dynamic tissue, undergoing
several morphological and physiological modifications over a lifetime
in connection with hormonal modulation and ageing. The main purpose
of this study was therefore to evaluate the efficacy of a set of proposed
forensic vaginal mRNA markers (CYP2B7P1, MUC4, MYOZ1) in women
from different age groups.
2. Materials and methods
Vaginal swabs were obtained through self-sampling from adult
consenting women in their reproductive years (R) (n=84) and in
postmenopausa (PM) (n= 55). Donors were asked to fill an anonymous
survey including information on menstrual cycle phase and sexual ac-
tivity in the 10 days before sampling. Subsets of swabs (n= 13–14),
designed as to minimize differences in the ratio between R and PM
samples and mean time since swab collection (7.3 months ± 0.4 SD),
were distributed to participating laboratories. RNA extraction, cDNA
synthesis, mRNA profiling using a 19-plex mRNA assay [1] and scoring
of results [2] was done according to protocols previously adopted in a
preparatory GeFI collaborative exercise [3]. For capillary electrophor-
esis, each participant used the available instrumentation (310, 3130,
3500 and SeqStudio genetic analyzers), and the settings (analytical
threshold, etc.) defined through internal laboratory validation.
3. Results
Nine out of ten laboratories returned complete results, corre-
sponding to a final sample set of 75 swabs from R donors and 50 swabs
from PM donors. mRNA profiling success rate (vaginal mucosa “ob-
served” according to scoring guidelines) across laboratories was on
average 86% (±8% SE) for R samples, and 83% (± 5% SE) for PM
samples. The observed difference in mRNA profiling success rate be-
tween the two age categories was not significant (p > 0.05,
Mann–Withney rank sum test).
There was also no significant correlation (p > 0.05, Spearman rank
test) between mRNA profiling success rate and time interval between
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swab collection and RNA extraction, which ranged from 6 to 20 months
with a median of 11 months.
Differential contribution of the three vaginal markers to mRNA
profiling results in the two age groups is summarized in Fig. 1.
In Fig. 1a, the percentage of peaks above analytical threshold ob-
served in mRNA profiling replicates (4 for each swab) is shown for each
vaginal marker. The average relative contribution of single vaginal
markers to total peak height (measured in rfu) observed for vaginal
markers within each mRNA profiling replicate is shown in Fig. 1b. In
this case, data from one participating laboratory that reported several
off-scale peaks for CYP2B7P1 and MUC4 were not considered in cal-
culations. A significant increase in average relative contribution to total
peak height of vaginal markers was observed for MUC4 in PM samples,
compared to R samples (p < 0.05, t test).
Percentages of tested swabs in which body fluids other than vaginal
mucosa were “observed” by mRNA profiling were the following: blood
(20%); menstrual secretions (21%); semen, not considering in scoring
calculations marker PRM1 specific for spermatozoa (21%); semen,
considering PRM1 in scoring calculations (5%); saliva (5%); nasal
mucosa (4%); skin (51%). The observation of semen (with and without
spermatozoa, depending on the presence/absence of PRM1 in at least
half of the PCR replicates), blood and menstrual secretions was then
considered in connection with available information on menstrual cycle
phase (n= 95) and sexual activity in the 10 days before sampling
(n=124). In donors who did not report sexual activity in the last 10
days, semen with and without spermatozoa was “observed” in 1% and
6% of cases, respectively. Semen with and without spermatozoa was
“not observed” by mRNA profiling in a large number of donors who
reported sexual activity in the 10 days before sampling: 37% and 30%
of cases, respectively. However, it must be underlined that the anon-
ymous survey did not differentiate between protected and unprotected
sexual activity. Menstrual secretion and blood were “observed” in do-
nors outside menstrual cycle in 12% and 9% of cases, respectively. On
the contrary, menstrual secretion and blood during menstrual cycle
were “not observed” in 7% and 6% of the tested samples, respectively.
4. Discussion
Of the three vaginal markers included in the tested multiplex, MUC4
was originally selected for forensic mRNA profiling through a
combination of literature and database searches [4] and it is known to
be expressed both in R and PM women [5]. On the contrary, CYP2B7P1
and MYOZ1 were originally identified as vaginal markers through
transcriptome profiling (RNA-Seq) of vaginal swab samples obtained
from two donors (26 and 30 yr old, respectively) [6]. The function of
CYP2B7P1 and MYOZ1 in vagina remains unknown and their expres-
sion in women from different age groups has not been previously in-
vestigated. The results obtained confirm that, in general, MYOZ1 is a
less sensitive vaginal marker compared to MUC4 and CYP2B7P1, both
in R and PM donors [3]. Overall, the three combined vaginal markers
included in the 19-plex mRNA profiling assay appear highly efficient in
identifying vaginal mucosa irrespective of the donors age category,
even in non-recent samples (6–20 months). A relative reduction of
amplification signal for CYP2B7P1 and MYOZ1, corresponding to a
significant relative increase of MUC4 was observed in vaginal swabs
from PM donors.
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Fig. 1. a) Average percentage of marker replicate peaks above analytical threshold (error bars indicate SE). b) Average relative contribution of each marker to total
peak height of vaginal markers in single replicates (error bars indicate SE). Asterisk indicates significance at p < 0.05.
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